Do women with breast cancer have a higher risk of atrial fibrillation?

Increased risk of atrial fibrillation in women with breast cancer depends on age and time since diagnosis, according to a new study published in HeartRhythm

Philadelphia, January 29, 2019

Patients with breast cancer may have an increased incidence of atrial fibrillation (AF), say researchers. A retrospective study in Denmark has found that women with breast cancer have an increased risk of developing AF within three years following their cancer diagnosis compared with other women of the same age. The results are published in HeartRhythm, the official journal of the Heart Rhythm Society and the Cardiac Electrophysiology Society.

According to the World Cancer Research Fund, breast cancer is the most common cancer in women worldwide and the second most common cancer overall. There were over two million new cases in 2018.  Investigators hypothesized that patients with breast cancer may have a lower threshold for developing AF as breast cancer induces inflammation, a known risk factor for AF.

“Modern treatment regimens ensure that approximately 80 percent of breast cancer patients become long-term survivors,” explained lead investigator Maria D’Souza, MD, of the Herlev and Gentofte Hospital, Cardiology Department, Hellerup, Denmark. “Healthy survivorship can be threatened, however, by long-term complications resulting from both the cancer and related treatments. Notably, increased frequencies of cardiovascular disease, especially heart failure and ischemic heart disease, have been observed in survivors. We hypothesized that women with breast cancer could also be more prone to developing AF because breast cancer induces inflammation.”

Using nationwide registries in Denmark, investigators analyzed the long-term incidence of AF in patients with breast cancer compared with the general population. They identified patients diagnosed with breast cancer between 1998 and 2015 and then matched 74,155 female breast cancer patients according to age and sex with 222,465 individuals from the general population (ratio 1:3). Long-term incidence of AF was estimated by cumulative incidence curves and multivariable Cox regression models.

The investigators found that female patients with breast cancer had an increased risk of AF, and that the risk was dependent on age and time since diagnosis. Patients less than 60 years old had a more than doubled risk in the first six months after diagnosis and an 80 percent higher risk from six months to three years after their diagnosis. Patients over 60 years old had a similar risk to the general population during the first six months but had a 14 percent increased risk from six months to three years after diagnosis.

“This study was the first to show that women with recent breast cancer had an increased risk of developing AF. Our findings should encourage doctors to focus on the risk of AF in patients with recent breast cancer in order to diagnose and treat as early as possible, and researchers to search for increased risk of AF looking at the cancer itself, treatment, genetic predisposition, and shared life style risk factors,” said Dr. D’Souza. “Ultimately, earlier treatment may result in better stroke prevention.”

In an accompanying editorial, Ankur Karnik, MD, of the Evans Department of Medicine, Cardiovascular Medicine Section, Boston University School of Medicine, Boston, MA, USA, and colleagues commented that this study provides valuable insights from a large nationwide cohort with results generalizable to women of European ancestry. However, they caution that there are several factors to be considered when interpreting the results. Follow-up was only three years, which may be too short a time for the cardiotoxic effects of breast cancer treatment to fully manifest. The multivariable Cox regression model used in the study did not account for competing risk of death – the three-year mortality risk was larger than the risk of AF in both groups.

The study does however suggest several substantive research questions. Can the risk of AF in patients with breast cancer be explained by shared risk factors? Is it a multiple-hit phenomenon in which a pro-inflammatory state and breast cancer treatments add insult to injury? Are there certain chemotherapeutic regimens or cumulative radiation doses that raise AF risk? Are there subsets of women with breast cancer at sufficient risk for AF who may merit more intensive monitoring?

“While we do not consider broad-based monitoring for AF in women with breast cancer is warranted at this time, the work of D’Souza et al. is a contribution to the burgeoning field of cardio-oncology and provides support for further research into the potentially bidirectional relationship between cancer and AF,” noted Dr. Karnik.


Notes for editors
The article is “Incidence of atrial fibrillation in conjunction with breast cancer,” by Maria D’Souza, MD, Lærke Smedegaard, MD, Christian Madelaire, MD, Dorte Nielsen, MD, DMSc, Christian Torp-Pedersen, MD, DMSc, Gunnar Gislason, MD, PhD, Morten Schou, MD, PhD, and Emil Fosbøl, MD, PhD ( The editorial is “Breast cancer and atrial fibrillation - A malignant combination?” by Ankur A. Karnik, MD, Emelia J. Benjamin, MD, ScM, and Ludovic Trinquart, PhD ( They will appear in HeartRhythm, volume 16, issue 3 (March 2019) published by Elsevier.

This study was funded by the Danish Heart Foundation, Copenhagen, Denmark (grant no. 15-R99-A5858) and the VELUX Foundations, Copenhagen, Denmark (grant no. 00012057).

Full text of these articles is available to credentialed journalists upon request; contact Jane Grochowski at +1 406 542 8397 or Journalists who wish to interview the study authors should contact Maria D’Souza at Ankur A. Karnik may be reached for comment via

About HeartRhythm
HeartRhythm, the official Journal of the Heart Rhythm Society and the Cardiac Electrophysiology Society, is a unique journal for fundamental discovery and clinical applicability. It integrates the entire cardiac electrophysiology (EP) community from basic and clinical academic researchers, private practitioners, engineers, allied professionals, industry, and trainees, all of whom are vital and interdependent members of our EP community.

About Elsevier
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers.

Media contact
Jane Grochowski, Publisher
+1 406 542 8397